Share This Article:

Gene Expression Changes in Colorectal Cancer during Metronomic Chemotherapy and High-Concentration Drug Administration

Abstract Full-Text HTML XML Download Download as PDF (Size:5813KB) PP. 679-689
DOI: 10.4236/jct.2015.68075    2,459 Downloads   2,899 Views  

ABSTRACT

5-fluorouracil (5-FU) and oxaliplatin, either alone or in combination, are widely used in chemotherapy for advanced colorectal cancer. Among chemotherapeutic strategies, metronomic chemotherapy has recently demonstrated promising efficacy against otherwise chemoresistant neoplasms. However, data on the efficacy of metronomic applications in cancer stem cells are lacking. This cell population is characterized by resistance to most chemotherapeutic models. In this study, we investigated the efficacy of metronomic chemotherapy and compared it with high-concentration administration of 5-FU and oxaliplatin and their combination in colon adenocarcinoma cells and colon cancer stem cells. We assessed changes in expression levels of specific genes involved in 5-FU and oxaliplatin resistance (thymidylate synthase, DNA (cytosine-5)-methyltransferase 1, dihydrofolate reductase, serine hydroxymethyltransferase, DNA excision repair protein, dihydropyrimidine dehydrogenase) in relation to drug administration schedule using quantitative real-time polymerase chain reaction. We also examined changes in cell viability. Metronomic chemotherapy showed greater efficacy in gene expression levels in colorectal cancer cells, while high, single-concentration administration was more effective in colon cancer stem cells. Regarding cell viability, no significant change was observed between metronomic and single-dose treatments. These results suggest that metronomic chemotherapy may be more effective than high-dose chemotherapy in some patients with colorectal cancer, though high, single-concentration administration may be more effective against cancer stem cells.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Apostolou, P. , Toloudi, M. , Kalliara, I. , Kipourou, V. , Tourna, I. and Papasotiriou, I. (2015) Gene Expression Changes in Colorectal Cancer during Metronomic Chemotherapy and High-Concentration Drug Administration. Journal of Cancer Therapy, 6, 679-689. doi: 10.4236/jct.2015.68075.

References

[1] Siegel, R., Desantis, C. and Jemal, A. (2014) Colorectal Cancer Statistics, 2014. CA: A Cancer Journal for Clinicians, 64, 104-117.
http://dx.doi.org/10.3322/caac.21220
[2] Cunningham, D., Atkin, W., Lenz, H.J., Lynch, H.T., Minsky, B., Nordlinger, B. and Starling, N. (2010) Colorectal Cancer. Lancet, 375, 1030-1047.
http://dx.doi.org/10.1016/S0140-6736(10)60353-4
[3] Chau, I. and Cunningham, D. (2002) Adjuvant Therapy in Colon Cancer: Current Status and Future Directions. Cancer Treatment Reviews, 28, 223-236.
http://dx.doi.org/10.1016/S0305-7372(02)00047-6
[4] Shim, B.Y., Lee, K.M., Cho, H.M., Kim, H.J., Cho, H.J., Yang, J., Kim, J.G. and Kim, H.K. (2005) Oxaliplatin/5-FU without Leucovorin Chemotherapy in Metastatic Colorectal Cancer. Cancer Research and Treatment, 37, 212-215.
http://dx.doi.org/10.4143/crt.2005.37.4.212
[5] Toloudi, M., Apostolou, P. and Papasotiriou, I. (2015) Efficacy of 5-FU or Oxaliplatin Monotherapy over Combination Therapy in Colorectal Cancer. Journal of Cancer Therapy, 6, 345-355.
http://dx.doi.org/10.4236/jct.2015.64037
[6] Kerbel, R.S. and Kamen, B.A. (2004) The Anti-Angiogenic Basis of Metronomic Chemotherapy. Nature Reviews Cancer, 4, 423-436.
http://dx.doi.org/10.1038/nrc1369
[7] Hermann, P.C., Huber, S.L., Herrler, T., Aicher, A., Ellwart, J.W., Guba, M., Bruns, C.J. and Heeschen, C. (2007) Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer. Cell Stem Cell, 1, 313-323.
http://dx.doi.org/10.1016/j.stem.2007.06.002
[8] Toloudi, M., Apostolou, P., Chatziioannou, M. and Papasotiriou, I. (2011) Correlation between Cancer Stem Cells and Circulating Tumor Cells and Their Value. Case Reports in Oncology, 4, 44-54.
http://dx.doi.org/10.1159/000324403
[9] Gradilone, A., Naso, G., Raimondi, C., Cortesi, E., Gandini, O., Vincenzi, B., Saltarelli, R., Chiapparino, E., Spremberg, F., Cristofanilli, M., et al. (2011) Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC): Prognosis, Drug Resistance and Phenotypic Characterization. Annals of Oncology, 22, 86-92.
http://dx.doi.org/10.1093/annonc/mdq323
[10] Dean, M. (2009) ABC Transporters, Drug Resistance, and Cancer Stem Cells. Journal of Mammary Gland Biology and Neoplasia, 14, 3-9.
http://dx.doi.org/10.1007/s10911-009-9109-9
[11] Livak, K.J. and Schmittgen, T.D. (2001) Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408.
http://dx.doi.org/10.1006/meth.2001.1262
[12] Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69-90.
http://dx.doi.org/10.3322/caac.20107
[13] Sahlberg, S.H., Spiegelberg, D., Glimelius, B., Stenerlow, B. and Nestor, M. (2014) Evaluation of Cancer Stem Cell Markers CD133, CD44, CD24: Association with AKT Isoforms and Radiation Resistance in Colon Cancer Cells. PLoS ONE, 9, e94621.
http://dx.doi.org/10.1371/journal.pone.0094621
[14] Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I.R., Lu, L., Irvin, D., Black, K.L. and Yu, J.S. (2006) Analysis of Gene Expression and Chemoresistance of CD133+ Cancer Stem Cells in Glioblastoma. Molecular Cancer, 5, 67.
http://dx.doi.org/10.1186/1476-4598-5-67
[15] Scharovsky, O.G., Mainetti, L.E. and Rozados, V.R. (2009) Metronomic Chemotherapy: Changing the Paradigm That More Is Better. Current Oncology, 16, 7-15.
http://dx.doi.org/10.3747/co.v16i2.420
[16] Vives, M., Ginesta, M.M., Gracova, K., Graupera, M., Casanovas, O., Capella, G., Serrano, T., Laquente, B. and Vinals, F. (2013) Metronomic Chemotherapy Following the Maximum Tolerated Dose Is an Effective Anti-Tumour Therapy Affecting Angiogenesis, Tumour Dissemination and Cancer Stem Cells. International Journal of Cancer, 133, 2464-2472.
http://dx.doi.org/10.1002/ijc.28259
[17] Sperone, P., Ferrero, A., Daffara, F., Priola, A., Zaggia, B., Volante, M., Santini, D., Vincenzi, B., Badalamenti, G., Intrivici, C., et al. (2010) Gemcitabine plus Metronomic 5-Fluorouracil or Capecitabine as a Second-/Third-Line Chemotherapy in Advanced Adrenocortical Carcinoma: A Multicenter Phase II Study. Endocrine-Related Cancer, 17, 445-453.
http://dx.doi.org/10.1677/ERC-09-0281
[18] Murakami, H., Ogata, Y., Akagi, Y., Ishibashi, N. and Shirouzu, K. (2011) Circulating Endothelial Progenitor Cells in Metronomic Chemotherapy Using Irinotecan and/or Bevacizumab for Colon Carcinoma: Study of Their Clinical Significance. Experimental and Therapeutic Medicine, 2, 595-600.
[19] Hackl, C., Man, S., Francia, G., Milsom, C., Xu, P. and Kerbel, R.S. (2013) Metronomic Oral Topotecan Prolongs Survival and Reduces Liver Metastasis in Improved Preclinical Orthotopic and Adjuvant Therapy Colon Cancer Models. Gut, 62, 259-271.
http://dx.doi.org/10.1136/gutjnl-2011-301585
[20] Yoshikawa, R., Kusunoki, M., Yanagi, H., Noda, M., Furuyama, J.I., Yamamura, T. and Hashimoto-Tamaoki, T. (2001) Dual Antitumor Effects of 5-Fluorouracil on the Cell Cycle in Colorectal Carcinoma Cells: A Novel Target Mechanism Concept for Pharmacokinetic Modulating Chemotherapy. Cancer Research, 61, 1029-1037.
[21] Longley, D.B., Harkin, D.P. and Johnston, P.G. (2003) 5-Fluorouracil: Mechanisms of Action and Clinical Strategies. Nature Reviews Cancer, 3, 330-338.
http://dx.doi.org/10.1038/nrc1074
[22] Jensen, S.A., Vainer, B., Witton, C.J., Jorgensen, J.T. and Sorensen, J.B. (2008) Prognostic Significance of Numeric Aberrations of Genes for Thymidylate Synthase, Thymidine Phosphorylase and Dihydrofolate Reductase in Colorectal Cancer. Acta Oncologica, 47, 1054-1061.
http://dx.doi.org/10.1080/02841860801942158
[23] Ichikawa, W., Uetake, H., Shirota, Y., Yamada, H., Nishi, N., Nihei, Z., Sugihara, K. and Hirayama, R. (2003) Combination of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Gene Expressions in Primary Tumors as Predictive Parameters for the Efficacy of Fluoropyrimidine-Based Chemotherapy for Metastatic Colorectal Cancer. Clinical Cancer Research, 9, 786-791.
[24] Steck, S.E., Keku, T., Butler, L.M., Galanko, J., Massa, B., Millikan, R.C. and Sandler, R.S. (2008) Polymorphisms in Methionine Synthase, Methionine Synthase Reductase and Serine Hydroxymethyltransferase, Folate and Alcohol Intake, and Colon Cancer Risk. Journal of Nutrigenetics and Nutrigenomics, 1, 196-204.
http://dx.doi.org/10.1159/000136651
[25] DiPaolo, A. and Chu, E. (2004) The Role of Thymidylate Synthase as a Molecular Biomarker. Clinical Cancer Research, 10, 411-412.
http://dx.doi.org/10.1158/1078-0432.CCR-1198-03
[26] Yu, Y., Kanwar, S.S., Patel, B.B., Nautiyal, J., Sarkar, F.H. and Majumdar, A.P. (2009) Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. Translational Oncology, 2, 321-328.
http://dx.doi.org/10.1593/tlo.09193
[27] Kim, Y., Joo, K.M., Jin, J. and Nam, D.H. (2009) Cancer Stem Cells and Their Mechanism of Chemo-Radiation Resistance. International Journal of Stem Cells, 2, 109-114.
http://dx.doi.org/10.15283/ijsc.2009.2.2.109
[28] Hollier, B.G., Evans, K. and Mani, S.A. (2009) The Epithelial-to-Mesenchymal Transition and Cancer Stem Cells: A Coalition against Cancer Therapies. Journal of Mammary Gland Biology and Neoplasia, 14, 29-43.
http://dx.doi.org/10.1007/s10911-009-9110-3
[29] Fioravanti, A., Canu, B., Ali, G., Orlandi, P., Allegrini, G., Di Desidero, T., Emmenegger, U., Fontanini, G., Danesi, R., Del Tacca, M., et al. (2009) Metronomic 5-Fluorouracil, Oxaliplatin and Irinotecan in Colorectal Cancer. European Journal of Pharmacology, 619, 8-14.
http://dx.doi.org/10.1016/j.ejphar.2009.08.020

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.